8-K: Aptose Biosciences Acquired by Hanmi, Reports 2025 Financials

Aptose Biosciences shareholders approved its acquisition by Hanmi Pharmaceutical, with the company also reporting its year-end 2025 financial results and positive clinical data for its AML therapy.

Summary

• Aptose shareholders approved the continuance of the Company from the Canada Business Corporations Act to the Business Corporations Act (Alberta) and the plan of arrangement for acquisition by HS North America Ltd., a wholly owned subsidiary of Hanmi Pharmaceutical Co. Ltd.
• Under the terms, Aptose shareholders (excluding Hanmi Purchasers and affiliates) will receive C$2.41 in cash per Common Share, representing a 28% premium over Aptose's 30-day VWAP of C$1.88 on the Toronto Stock Exchange.
• The Court of Kings Bench of Alberta has issued a final order approving the Arrangement, with closing expected by the end of April 2026, subject to customary closing conditions including regulatory approvals.
• Aptose presented positive clinical data for its tuspetinib (TUS)+venetoclax (VEN)+azacitidine (AZA) triplet therapy in newly diagnosed AML patients at the ASH 2025 Annual Meeting.
• The TUS+VEN+AZA triplet demonstrated 90% high-quality clinical responses (CR/CRh) across 40 mg, 80 mg, and 120 mg dose levels, and 100% at the higher 80 mg and 120 mg dose levels, with 78% MRD negativity in responding subjects.
• The therapy was well tolerated with no dose-limiting toxicities (DLTs) across all evaluable TUS dose levels, no drug-related deaths, differentiation syndrome, QTc prolongation, or CPK elevation reported.
• Net loss for the year ended December 31, 2025, was $25.5 million, a slight increase from $25.4 million for the comparable period in 2024.
• Cash, cash equivalents, restricted cash, and restricted cash equivalents totaled $4.1 million as of December 31, 2025.
• The company does not have sufficient cash to fund operations and relies on advances made by Hanmi, which provided over US$41 million in debt facilities over the past 18 months.
• Research and development expenses decreased by $3.8 million to $11.3 million for the year ended December 31, 2025, primarily due to the conclusion of APTIVATE clinical trial activities and lower manufacturing costs for tuspetinib, as well as lower headcount.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development for shareholders, as the acquisition provides a premium exit for a company facing significant financial challenges, while ensuring the continued development of a promising drug candidate.

Positives

• Shareholders approved the acquisition by Hanmi Pharmaceutical, providing a C$2.41 per share cash payout, which represents a 28% premium over the 30-day VWAP.
• The Court of Kings Bench of Alberta issued final approval for the Arrangement, moving the acquisition closer to completion.
• TUS+VEN+AZA triplet therapy demonstrated promising safety and high efficacy in newly diagnosed AML patients, including those with adverse genetic subgroups.
• High-quality clinical responses (CR/CRh) of 90% across 40 mg, 80 mg, and 120 mg dose levels, and 100% at 80 mg and 120 mg, were observed.
• MRD negativity was achieved in 78% of responding subjects, indicating deep remissions.
• The therapy was well tolerated with no dose-limiting toxicities (DLTs) across all evaluable TUS dose levels, and no drug-related deaths or significant cardiac/muscle issues reported.
• Preliminary findings at the 160 mg dose level show patients achieving early blast clearance with MRD-negativity and formal responses.
• Research and development expenses decreased by $3.8 million to $11.3 million in 2025, reflecting cost management efforts.

Negatives

• Net loss slightly increased to $25.5 million in 2025 from $25.4 million in 2024.
• Cash, cash equivalents, restricted cash, and restricted cash equivalents significantly decreased to $4.1 million as of December 31, 2025, from $6.7 million in 2024.
• Working capital deteriorated from a positive $4.43 million in 2024 to a deficit of $2.86 million in 2025.
• Shareholders deficit worsened substantially from $(4.543) million in 2024 to $(27.167) million in 2025.
• Long-term liabilities increased significantly to $27.873 million in 2025 from $10.211 million in 2024, largely due to debt facilities from Hanmi.
• The company explicitly stated it does not have sufficient cash to fund operations and relies on advances from Hanmi, indicating severe financial distress.

Risks

• The Arrangement may not be completed on the terms, conditions, or timing currently contemplated, or at all, due to a failure to obtain or satisfy, in a timely manner or otherwise, customary closing conditions including regulatory approvals.
• Inability to obtain the capital required for research and operations if the acquisition does not proceed or if future funding is needed.
• Inherent risks in early-stage drug development, including demonstrating efficacy in larger trials.
• Development time/cost and the regulatory approval process for new drug candidates.
• Ability to find and enter into agreements with potential partners for future development or commercialization.
• Ability to attract and retain key personnel, especially during a transition period.
• Changing market and economic conditions that could impact the biotechnology sector.
• Unexpected manufacturing defects or supply chain issues for drug candidates.
• The evolving regulatory and political landscape and the funding of government programs.

Future Outlook

The Arrangement with Hanmi Pharmaceutical is expected to be completed by the end of April 2026, subject to customary closing conditions including regulatory approvals. The company also anticipates presenting the next set of clinical data for TUS+VEN+AZA at the EHA2026 Congress in June.

Management Comments

• "We are pleased that shareholders have approved our proposed arrangement with Hanmi, which enables us to continue and expand the development of the TUS+VEN+AZA triplet, which has shown promising response rates and safety as a mutation agnostic therapy across a diverse population of patients newly diagnosed with AML."
• "We are extremely grateful for Hanmis ongoing support, including its significant financial support under difficult circumstances over the past two years."
• "The data in our clinical trial continue to support the promise of TUS+VEN+AZA therapy, and we look forward to presenting the next set of data at the EHA2026 Congress in June."

Industry Context

StockSavvy.ai notes that the acquisition of Aptose Biosciences by Hanmi Pharmaceutical reflects a broader trend in the biotechnology sector where larger pharmaceutical companies acquire smaller clinical-stage firms to gain access to promising drug candidates, especially in high-need areas like oncology. The positive clinical data for tuspetinib in AML, a challenging cancer, positions it as a valuable asset, potentially reducing development risks for Hanmi. This strategic move allows Aptose's promising therapy to continue development with more robust financial backing, a common outcome for cash-strapped biotechs with compelling early-stage results.

Comparison to Industry Standards

• The 90% CR/CRh rate and 78% MRD negativity for TUS+VEN+AZA in newly diagnosed AML patients, including those with adverse genetic subgroups like biallelic TP53/complex karyotype and RAS mutations, are highly competitive. For context, standard venetoclax-azacitidine regimens typically show CR/CRh rates around 60-70% in similar patient populations, with MRD negativity rates varying but often lower in high-risk groups.
• The absence of dose-limiting toxicities (DLTs) and drug-related deaths, QTc prolongation, or CPK elevation reported for TUS+VEN+AZA suggests a favorable safety profile compared to some existing AML therapies that can have significant side effects.
• The acquisition premium of 28% over the 30-day VWAP is within the typical range for biotech acquisitions, reflecting both the strategic value of the asset and the financial distress of the acquired company.

Corporate Governance

Related Party Transactions

• Hanmi Pharmaceutical, through its subsidiary HS North America Ltd., is acquiring Aptose Biosciences.
• Hanmi Pharmaceutical provided debt facilities totaling over US$41 million to Aptose over the past 18 months.

Stakeholder Impact

• Shareholders will receive C$2.41 in cash per Common Share, representing a 28% premium over the 30-day VWAP, providing a liquidity event and a premium exit from a financially distressed company.
• Employees may experience integration and potential restructuring as the company transitions under Hanmi's ownership, though specific details are not provided.
• Patients (potential customers) will benefit from the continued development of tuspetinib under Hanmi's robust financial backing, increasing the likelihood of this promising AML therapy reaching the market.
• Hanmi Pharmaceutical, as a significant creditor through its debt facilities, is now acquiring the company, which will resolve its creditor position and integrate Aptose's assets into its portfolio.

Next Steps

• Completion of the Arrangement by the end of April 2026, subject to customary closing conditions including regulatory approvals.
• Presentation of the next set of clinical data for TUS+VEN+AZA at the EHA2026 Congress in June.

Key Dates

Recommendation

The acquisition by Hanmi Pharmaceutical at a 28% premium provides a clear exit strategy for existing shareholders, making a 'buy' or 'sell' recommendation less relevant for immediate action given the impending close. A 'hold' is appropriate for shareholders awaiting the finalization of the C$2.41 per share cash payment. For new investors, the stock is essentially a cash equivalent at the offer price, with limited upside or downside until the transaction closes.

Keywords

Aptose Biosciences, Hanmi Pharmaceutical, acquisition, AML, acute myeloid leukemia, tuspetinib, TUS+VEN+AZA, oncology, clinical trial, precision medicine, corporate governance, financial results, 8-K, merger, biotechnology, drug development